Why did PHASQ stock fall so sharply today?

PHASQ stock dropped due to thin liquidity, the company’s Chapter 11 background, and investor risk aversion toward clinical-stage biotech. Low volume magnified the move on PNK and left wide bid-ask spreads.

What are the main financial risks for PHASQ stock?

Key financial risks include ongoing cash burn (operating cash flow per share **-1.61**), potential dilution, negative EPS **-2.14**, and uncertain restructuring outcomes that can eliminate common equity value.

What catalysts could support a PHASQ stock recovery?

Catalysts include positive Phase III data for bentracimab, a credible financing or partnership, or restructuring terms that preserve equity claim value. Each would materially change valuation dynamics.

How does Meyka AI grade PHASQ stock?

Meyka AI rates PHASQ with a score out of 100: **62.85**, Grade **B**, Suggestion **HOLD**. The grade weighs benchmarks, sector, metrics, growth, forecasts, and consensus; it is informational, not investment advice.

US Stocks

PHASQ stock plunges 99.00% to $0.000001 on 23 Feb 2026: key analyst takeaway

ByDanny Kontos February 23, 2026

PHASQ stock fell sharply during market hours on 23 Feb 2026, trading at $0.000001 on the PNK exchange in the United States, down -99.00% from the prior close. Volume was light at 2,500.00 shares versus an average of 22,310.00, and the company still carries negative EPS of -2.14. Investors reacted to the company’s past Chapter 11 restructuring and thin liquidity. This note explains the drivers behind the drop, key financial metrics, and a risk-focused outlook for PhaseBio Pharmaceuticals, Inc. (PHASQ) in USD